Capping Prescription Costs Act of 2024
Latest Action
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Capping Prescription Costs Act of 2024 is a Senate bill introduced in the 118th Congress aimed at limiting the out-of-pocket expenses individuals pay for prescription medications. The bill was read twice and referred to the Committee on Health, Education, Labor, and Pensions but did not advance further and is currently classified as failed or expired. No official summary or full text is available, limiting detailed analysis of specific provisions or mechanisms within the bill.
This bill sought to reduce prescription drug costs for consumers but did not progress beyond committee referral and ultimately expired without enactment.
- The bill focuses on capping prescription drug costs to make medications more affordable.
- It was introduced in the Senate during the 118th Congress but did not advance past committee referral.
- No official summary or full text is publicly available, restricting detailed policy analysis.
['Patients and consumers who require prescription medications', 'Healthcare providers indirectly through improved patient medication adherence', 'Potentially health insurance plans and government health programs if cost savings occur']
['Lack of publicly available full bill text and summary limits understanding of implementation details and enforcement mechanisms', 'Potential fiscal impact on pharmaceutical companies and insurers depending on cost cap specifics', 'Oversight and authority for enforcing cost caps are unclear without full text', 'Tradeoffs between drug pricing controls and pharmaceutical innovation or market dynamics cannot be assessed']
The bill was introduced in the Senate and referred to the Committee on Health, Education, Labor, and Pensions during the 118th Congress but did not advance further. The failure or expiration status indicates it was not enacted into law. The policy area is health, specifically addressing prescription drug costs, a topic of ongoing legislative interest.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['If enacted, capping prescription costs could improve medication adherence and health outcomes for patients.', 'Potential shifts in pharmaceutical pricing strategies or insurance plan designs might occur in response to cost caps.', 'Government healthcare programs could experience budgetary impacts depending on cost-sharing changes.']
The absence of the full bill text and official summary significantly limits the ability to assess the bill's detailed provisions, enforcement mechanisms, and fiscal implications. Transparency in legislative documentation is essential for informed public and stakeholder review. The bill's failure to advance beyond committee referral suggests limited legislative momentum during the 118th Congress.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.